Dornase alfa biobetter - Pharmsynthez/Xenetic Biosciences

Drug Profile

Dornase alfa biobetter - Pharmsynthez/Xenetic Biosciences

Alternative Names: Bronchozym; Polysialylated DNase; PSA-DNase; PulmoXen

Latest Information Update: 11 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pharmsynthez; Xenetic Biosciences
  • Developer Pharmsynthez
  • Class Antifibrotics; Biobetters; Recombinant proteins
  • Mechanism of Action Deoxyribonuclease 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cystic fibrosis

Most Recent Events

  • 27 Mar 2017 Xenetic Biosciences has patent protection for PolyXen™ platform technology in Europe, Asia and North America, including USA
  • 17 Mar 2016 Phase I development is ongoing in Belarus, Russia and Ukraine
  • 31 Dec 2013 Phase-I clinical trials in Cystic fibrosis (in volunteers) in Russia, Ukraine and Belarus (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top